Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

(MedPage Today) -- The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK inhibitor.
The approval stipulates use of alectinib...